Bevacizumab is a monoclonal antibody used in cancer therapy to inhibit vascular endothelial growth factor (VEGF), thereby reducing tumor blood vessel formation. It’s administered intravenously and is part of targeted therapy regimens. The term itself is a pharmaceutical name, not a common noun, and is pronounced with emphasis on a specific syllable pattern typical of biomedical nomenclature.
Full pronunciation guide
